Cardiorespiratory Fitness, Apolipoprotein E Genotype, and Cognitive Functions: A Prospective Study

Sponsor
National Taiwan Normal University (Other)
Overall Status
Completed
CT.gov ID
NCT05652140
Collaborator
(none)
180
1
34
5.3

Study Details

Study Description

Brief Summary

The current research project aims to investigate the interaction of cardiorespiratory fitness (CRF) and the ApoE genotype with neurocognitive functions.

Condition or Disease Intervention/Treatment Phase
  • Other: Data collections

Detailed Description

The current research project aims to investigate the interaction of cardiorespiratory fitness (CRF) and the ApoE genotype with neurocognitive functions. The three main purposes of the current research project seek to achieve:

  1. An exploration of the associations of, as well as the interactions between, CRF assessed at the Baseline Stage, and the ApoE genotype, along with cognitive functions in cognitively healthy late-middle-aged older adults.

  2. The employing of an event-related potential (ERP) to investigate the associations between the baseline CRF, the ApoE genotype, and cognitive functions in cognitively healthy late-middle-aged older adults, as well as the potential underlying neuroelectrical mechanisms.

  3. An investigation of the interactions between the changes of CRFs assessed at the Baseline and the Follow-Up Stages and the ApoE genotype in relation to neurocognitive function, as well as the underlying neuroelectrical mechanisms, in cognitively healthy late-middle-aged older adults.

Study Design

Study Type:
Observational
Actual Enrollment :
180 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Cardiorespiratory Fitness and the Apolipoprotein E (ApoE) Genotype and Its Interaction With Cognitive Functions and Cognitive Decline in Late-Middle-Aged Older Adults: A Prospective Study
Actual Study Start Date :
Jul 1, 2018
Actual Primary Completion Date :
Apr 1, 2021
Actual Study Completion Date :
May 1, 2021

Arms and Interventions

Arm Intervention/Treatment
High-Risk with increased CRF

ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.

Other: Data collections
Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.

High-Risk with decreased CRF

ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.

Other: Data collections
Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.

Low-Risk with increased CRF

Non-ApoE e4 carriers with increased CRF from Baseline to the Follow-Up Stages.

Other: Data collections
Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.

Low-Risk with decreased CRF

Non-ApoE e4 carriers with decreased CRF from Baseline to the Follow-Up Stages.

Other: Data collections
Data collections of cognitive function, neuroelectrical activities, ApoE genotype, and physical fitness.

Outcome Measures

Primary Outcome Measures

  1. Changes in inhibitory performance: Stroop task [30 minutes each at the Baseline and the Follow-Up Stages.]

    Inhibitory performance was assessed using the computerized Stroop task at the baseline and at the follow-up assessments. Changes in inhibitory performance from Baseline to the Follow-Up Stages were assessed.

  2. Changes in higher order executive performance: Tower of London Test [25 minutes each at the Baseline and the Follow-Up Stages.]

    Higher order executive performance was assessed using the Tower of London Test at the baseline and at the follow-up assessments. Changes in higher order executive performance from Baseline to the Follow-Up Stages were assessed.

  3. Changes in neuroelectrical activities [30 minutes each at the Baseline and the Follow-Up Stages.]

    The neuroelectrical activities during the Stroop task were recorded and analyzed using the Neuroscan system. Changes in the neuroelectrical activities from Baseline to the Follow-Up Stages were assessed.

Secondary Outcome Measures

  1. ApoE genotype [5 minutes at the Baseline Stage.]

    Based on the genetic biomarkers (rs429358 and rs7412), participants' ApoE genotype was determined.

  2. Physical fitness measurements: Changes in aerobic fitness [20 minutes each at the Baseline and the Follow-Up Stages.]

    Participants' aerobic fitness was estimated using the submaximal cycle ergometer test at the baseline and at the follow-up assessments. Changes in aerobic fitness from Baseline to the Follow-Up Stages were assessed.

Eligibility Criteria

Criteria

Ages Eligible for Study:
50 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • right handed

  • no history of cardiorespiratory disease

  • normal or corrected-to-normal vision based on the 20/20 standard

  • no risk of performing physical activities, as measured by the Physical Activity Readiness Questionnaire

Exclusion Criteria:
  • the scores of Mini-Mental Status Examination (MMSE) < 25 and cognitively intact upon study entry

  • history of psychiatric or neurological diseases

  • color-blindness

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of Physical Education and Sport Sciences, National Taiwan Normal University Taipei Taiwan 106308

Sponsors and Collaborators

  • National Taiwan Normal University

Investigators

  • Study Director: Yu-Kai Chang, Ph.D., Department of Physical Education and Sport Sciences, National Taiwan Normal University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Yu-Kai Chang, Professor, National Taiwan Normal University
ClinicalTrials.gov Identifier:
NCT05652140
Other Study ID Numbers:
  • PACNL_APOE_PROSPECTIVE
First Posted:
Dec 15, 2022
Last Update Posted:
Dec 16, 2022
Last Verified:
Dec 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Yu-Kai Chang, Professor, National Taiwan Normal University

Study Results

No Results Posted as of Dec 16, 2022